The role of internal tandem duplication of fms-like tyrosine kinase 3 (FLT3/ITD), mutations at tyrosine kinase domain (FLT3/ TKD) and N-ras mutations in the transformation of myelodysplastic syndrome (MDS) to AML was investigated in 82 MDS patients who later progressed to AML; 70 of them had paired marrow samples at diagnosis of MDS and AML available for comparative analysis. Five of the 82 patients had FLT3/ITD at presentation. Of the 70 paired samples, seven patients acquired FLT3/ITD during AML evolution. The incidence of FLT3/ITD at diagnosis of MDS was significantly lower than that at AML transformation (3/70 vs 10/70, Po0.001). FLT3/ITD( þ ) patients progressed to AML more rapidly than FLT3/ITD(À) patients (2.570.5 vs 11.971.5 months, P ¼ 0.114). FLT3/ITD( þ ) patients had a significantly shorter survival than FLT3/ITD(À) patients (5.671.3 vs 18.071.7 months, P ¼ 0.0008). After AML transformation, FLT3/ITD was also associated with an adverse prognosis. One patient had FLT3/TKD mutation (D835Y) at both MDS and AML stages. Additional three acquired FLT3/TKD (one each with D835 H, D835F and I836S) at AML transformation. Five of the 70 matched samples had N-ras mutation at diagnosis of MDS compared to 15 at AML transformation (Po0.001), one lost and 11 gained N-ras mutations at AML progression. Coexistence of FLT3/TKD and N-ras mutations was found in two AML samples. N-ras mutations had no prognostic impact either at the MDS or AML stage. Our results show that one-third of MDS patients acquire activating mutations of FLT3 or N-ras gene during AML evolution and FLT3/ITD predicts a poor outcome in MDS.
Introduction
Myelodysplastic syndrome (MDS) is a heterogeneous group of clonal hematopoietic stem cell disorders, characterized by ineffective hematopoiesis, refractory cytopenias and a tendency to progress into acute myeloid leukemia (AML). 1 The genetic aberrations in MDS have been studied over the last decade. Cytogenetic and molecular data provide evidence that MDS is characterized by a step-wise genetic progression. 2 As accumulation of genetic alterations is closely associated with leukemia progression of MDS, MDS serves as an extremely useful model for studying the abnormal genetic events from the preleukemia state to AML transformation. In adult MDS, disease progression has been described to be associated with p53 mutations and hypermethylation of p15 INK4b . [3] [4] [5] It has been known that activating mutations of ras gene or other disturbance in RAS signaling pathways leads to the uncontrolled growth factorindependent proliferation of hematopoietic progenitors. 6, 7 N-ras mutations have been previously extensively studied in MDS; however, the reported incidence of N-ras mutations in MDS at initial diagnosis varied considerably. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] Furthermore, the role of N-ras mutations in the prognosis and in the evolution of AML in MDS appears to be controversial. 8, 10, 11, [16] [17] [18] [19] Efforts are in progress to determine the prognostic significance of additional genetic aberrations. The fms-like tyrosine kinase 3 (FLT3) gene, located at chromosome 13q12 in humans, 20 encodes a class III receptor tyrosine kinase and plays an important role in hematopoiesis. 21 Two distinct types of FLT3-activating mutations have been identified in a subset of patients with AML. An internal tandem duplication (ITD) in the juxtamembrane domain of the FLT3 (FLT3/ITD) was found in 20-25% of adult AML and was associated with a poor prognosis. [22] [23] [24] [25] [26] [27] Point mutations at tyrosine kinase domain of FLT3 gene (FLT3/TKD) have been reported in 5-10% of AML. 28, 29 Previous studies on FLT3/ITD or FLT3/TKD mutations in MDS were examined either at initial presentation or only at AML transformation. 27, 28, 30, 31 Data of systematic study comparing the mutation status of FLT3 gene in the matched paired samples at both MDS and AML phases have not been available yet.
As mutant receptors of both FLT3/ITD and FLT3/TKD induce factor-independent proliferation through constitutive tyrosine phosphorylation and activation of the downstream STATS and RAS/MAPK pathways in the experimental system, [32] [33] [34] [35] [36] it is of particular interest to examine multiple genetic alterations associated with AML progression in MDS. In the present study, mutations of FLT3/ITD, FLT3/TKD and N-ras were investigated in 70 matched patient samples at diagnosis of MDS and after progression to AML and the mutations were correlated with clinicohematologic features and outcome. To the best of our knowledge, the present study is the first report of simultaneous analysis of activating mutations of FLT3 and N-ras genes on paired samples from a large number of patients with MDS before and after AML transformation. Our results demonstrate that acquisition of FLT3 or N-ras mutations is associated with the progression to AML in one-third of MDS patients, suggesting that these mutations play a role in the AML transformation.
Materials and methods

Patients and samples
Beginning in November 1991, patients with de novo MDS were diagnosed, treated and had been followed until death or for periods of up to 119 months in the single center, HematologyOncology division of Chang Gung Memorial Hospital. As of May 2003, 82 patients had progressed to AML; 70 of them had matched paired samples both at initial presentation and at AML transformation available for comparative analysis. The bone marrow (BM) samples were obtained with informed consent. The study was approved by the Institutional Review Board of Chang Gung Memorial Hospital. BM samples obtained from 82 patients at presentation of MDS and from 62 patients at the time of AML transformation were enriched by Ficoll-Hypaque (1.077 g/ml, Amersham Pharmacia, Buckinghamshire, UK) density-gradient centrifugation and cryopreserved in 10% dimethyl sulfoxide and 20% fetal bovine serum at À701C or in liquid nitrogen until test. Additional eight patients did not have frozen AML samples available; their samples were obtained from stained archived BM aspirate smears that had been stored in room temperature for up to 12 years.
The morphologic subtypes of MDS and AML were classified according to the French-American-British (FAB) criteria. [37] [38] [39] There were 10 refractory anemia (RA), one refractory anemia with ringed sideroblasts (RARS), 33 refractory anemia with excess blasts (RAEB), 11 chronic myelomonocytic leukemia (CMML) and 27 RAEB in transformation (RAEB-T). The percentage of marrow blasts was greater than 30% at AML transformation. The FAB subtypes at AML transformation were five AML-M0, one M1, 42 M2, 13 M4, three M6 and 18 unclassified. Cytochemical study and immunophenotypic analysis were performed at AML transformation. Cytogenetic analysis was performed at the time of initial diagnosis of MDS and/or at AML transformation. In all, 74 patients had data available for the calculation with the International Prognostic Scoring System (IPSS). 40 All MDS patients were managed with supportive care after initial presentation, except that three younger RAEB patients were treated with combination chemotherapy consisting of daunomycin and cytarabine (Ara-C) in the MDS stage, and another 15 patients, mainly of CMML with high WBC counts, received low-dose Ara-C or oral chemotherapeutic agents of 6-thioguanine, or hydroxyurea before AML transformation. Of the 70 patients with matched paired samples, 27 patients received standard induction chemotherapy with daunomycin and Ara-C after AML transformation, with two of them also undergoing allogeneic peripheral blood stem cell transplantation; additional 16 patients were treated with low-dose Ara-C and/or oral chemotherapeutic agents, the remaining 27 patients received supportive treatment exclusively.
Genomic DNA polymerase chain reaction (PCR) assay followed by sequence analysis for detection of FLT3/ITD and FLT3/TKD Genomic DNA was extracted from frozen BM cells by use of a DNA extraction kit (Puregene Gentra Systems, Minneapolis, MN, USA) according to the manufacturer's instructions. DNAs extracted from archived BM aspirate smears were carried out by using the methods as described by Fey et al, 41 with minor modification. The DNA PCR assay for the detection of FLT3/ITD, genescan analysis to determine the ITD mutant level and sequencing of the duplicated fragments of FLT3/ITD were performed as described previously. 42 Analysis was repeated on all samples with aberrant band(s). The sensitivity of this PCR assay could detect FLT3/ITD levels at 1% of the mutant DNA. 42 The restriction fragment length polymorphism-mediated PCR assay with EcoRV digestion followed by sequencing was used to detect the mutations at codons 835 and 836 of FLT3 as reported by Yamamoto et al, 28 with minor modification as described previously. 43 
Detection of N-ras mutations
Genomic DNA samples from 64 patients were analyzed for point mutations at codons 12, 13 and 61 of the N-ras gene by using PCR amplification of exons 1 and 2. The PCR assay was performed on a mixture of 25 ml containing 100 ng DNA with 0.625 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA), 1 Â PCR buffer, 1.5 mM MgCl 2 , 200 mM deoxyribonucleotide triphosphate (dNTP), and 1 mM each forward primer of 5 0 -GACTGAGTACAAACTGGTGG-3 0 (NRas-F1), and reverse primer of 5 0 -TGCATAACTGAATGTATACCC-3 0 (NRas-R1) for exon 1, which amplifies codons 12 and 13; and forward primer of 5 0 -CAAGTGGTTATAGATGGTGAAACC-3 0 (NRas-F2) and reverse primer of 5 0 -AAGATCATCCTTTCAGAGAAAATAAT-3 0 (NRas-R2) for exon 2, which amplifies codon 61. 44 PCR was performed in a 9600 thermal cycler (Applied Biosystems, Foster City, CA, USA) with a program consisting of an initial preheating at 941C for 5 min followed by denaturation at 941C for 1 min, 601C for 1 min and 721C for 1 min, for total 40 cycles, and a final extension at 721C for 10 min. The PCR products were analyzed by electrophoresis on 2% Nusieve agarose gel (BioWhittaker Molecular Applications, Rockland, ME, USA) stained with ethidium bromide, and visualized under a UV lamp. The PCR bands were cut out from the gel, purified and directly sequenced in both directions with the BigDye Terminator Cycle Sequencing Ready Reaction kit, which contained AmpliTaq DNA polymerase FS (Applied Biosystems), on an automated ABI PRISM 377 DNA sequencer (Applied Biosystems) according to the manufacturer's instructions. RNA samples from six patients were available for cDNA PCR assay. The extraction of RNA and reverse transcription reaction were carried out as described previously. 42 The cDNA PCR was performed as that for DNA PCR, except that only one primer set was used (forward primer of 5 0 -CTGTGGTCCTAAATCTGTCC-3 0 , and reverse primer of 5 0 -CAGTGCAGCTTGAAAGTGG-3 0 ). A fragment of 682 bp was amplified, which covers codons 12, 13 and 61. Direct sequencing of the PCR products was carried out as described above. Nine samples were analyzed with DNA and cDNA PCR assays and both methods yielded identical results.
Identification of the two N-ras mutations at codon 12 in a patient with RAEB-T The PCR product in the patient with two G to A substitution at codon 12 of N-ras gene was cloned into the pCR II-TOPO cloning vector (Invitrogen, Carlsbad, CA, USA) and then screened with mutation-specific PCR amplification. The PCR reaction was carried out with a 25-ml mixture containing 100 ng DNA, 200 mM dNTP, 60 mM Tris-hydrochloride (pH 8.5), 15 mM ammonium sulfate, 1.5 mM MgCl 2 , 5% acetamide, 0.625 U Taq DNA polymerase (Invitrogen, Carlsbad, CA, USA), and 1 mM each forward primer of 5 0 -GTGGTGGTTGGAGCAG-3 0 (G34W) for wild-type G34 or 5 0 -GTGGTGGTTGGAGCAA-3 0 (G34M) for mutant G34A, and the same reverse primer of NRas-R1. The PCR program was the same as described above for N-ras mutation analysis except for annealing at 581C for 1 min. Only the perfectly matched pairs of primers gave the desired products. A DNA fragment was amplified with G34M and NRas-R1 primers when G34A (Gly12Ser) mutant was present, whereas a DNA fragment was amplified with G34W and NRas-1 primers when only wild-type G34 was present. G35A (Gly12Asp) mutation was detected with the identical PCR conditions except that a different forward primer of 5 0 -GGTGGTTGGAGCAGG-3
and N-ras mutations in MDS and AML evolution L-Y Shih et al 467 (G35M) for mutant G35A was used with the same reverse primer NRas-R1. The respective colonies were chosen and cultured in LB medium. Plasmid DNAs were extracted and then sequenced.
Sensitivity of PCR assay for the detection of N-ras mutations
DNA isolated from the leukemic cells of a patient with CMML who had a 100% Gly12Asp of N-ras was serially diluted by mixing with the DNA obtained from cells that lacked N-ras mutation at codon 12, to make 10, 5, and 2% positive DNAs, and then analyzed by PCR amplification followed by direct sequencing as described above. The sensitivity of the PCR assay for the detection of N-ras mutation was at a level of 2-5% positive DNA ( Figure 1 ). groups. Kaplan-Meier analysis was used to determine the survival data. Difference in survival between groups was evaluated by the log-rank test. The correlation between the percentage of blasts in BM or peripheral blood (PB) and the level of mutations was analyzed by linear regression. The statistic analysis was performed by using a software of SPSS 8.0 for Windows (SPSS Inc., Chicago, USA). For all analyses, the Pvalues were two-tailed and o0.05 was considered statistically significant.
Statistical analysis
Results
Frequencies, mutation patterns and levels of FLT3/ITD at MDS and AML transformation
Of the 82 patients who later developed AML, FLT3/ITD was detected in one of 33 patients with RAEB, one of 11 patients with CMML and three of 27 patients with RAEB-T at initial presentation; ITD was absent in all the 11 patients with RA or RARS. AML transformation occurred at a median time of 6.2 months (range, 1-72 months) following the initial diagnosis of MDS. Of the 70 paired samples analyzed, FLT3/ITD was detected at both stages in three patients, one CMML and two RAEB-T at diagnosis of MDS. Additional seven patients, two with RA, one each with RAEB and CMML and three with RAEB-T, carrying exclusively wild-type FLT3 at initial presentation, acquired FLT3/ITD at the time of AML transformation. In the remaining 60 patients, FLT3/ITD was absent at both MDS and AML phases. The incidence of FLT3/ITD was significantly higher at diagnosis of AML than that at MDS (10/70 vs 3/70, Po0.001).
Of the 12 patients in whom only samples at MDS stage were available for study, one with RAEB and the other with RAEB-T had FLT3/ITD at presentation. Sequence analysis revealed that all ITD mutations were in-frame and the duplicated fragments were within exon 14 in all our patients, with three of them having nucleotides insertion.
Genescan analysis showed that one patient had a single ITD mutation with a level of 6.6% at initial diagnosis of RAEB-T, the identical mutation was also present at AML transformation but at a much higher level (45.9%) (Figure 2a) . The other patient with CMML had three ITD mutations, and the total mutant level was Sensitivity of PCR assay followed by direct sequencing for detection of N-ras mutations. Genomic DNA isolated from a sample harboring 100% (biallelic) N-ras mutant was diluted by mixing with various amounts of mutation-negative DNA to yield final concentrations of positive DNA of N-ras mutations at levels of 10% (a), 5% (b) and 2% (c). The sensitivity of the assay was at a level of 2-5% of mutant DNA.
Figure 2
Genescan analysis of FLT3/ITD levels. The PCR assay was performed with fluorescein-labeled primers and analyzed with an automated DNA sequencer. The area under the curve was calculated for each allele using Genescan software. M1-M3 indicates FLT3/ITD mutations of different sizes and levels; WT, wild-type FLT3. FLT3/TKD mutations in paired samples from patients with MDS at presentation and AML progression
Of the 82 patients with later AML progression, FLT3/TKD mutation was found in only one patient with RAEB-T at initial presentation. Sequence analysis showed a mutation type of Asp835Tyr (Figure 3a) , which was also present at the time of AML transformation 3.4 months following initial presentation. FLT3/TKD mutation was absent when she achieved a complete remission after induction chemotherapy; the same FLT3/TKD mutation was detected again when she had a relapse of AML 9 months later. Additional three patients, two RAEB and one RAEB-T, without FLT3/TKD mutation at diagnosis of MDS, acquired a mutation of Ile836Ser (Figure 3b ), Asp835His ( Figure 3c ) and Asp835Phe (Figures 3d and e) , respectively, at AML transformation. 
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Four patients had N-ras mutations of the same type at both MDS and AML stages. One patient with RAEB lost N-ras mutation at AML evolution, whereas 11 patients acquired N-ras mutations at AML transformation. Mutations at codon 12 were detected in six patients, at codon 13 in one and at codon 61 in nine patients. One patient harbored two N-ras mutations at codon 12, Gly12Ser and Gly12Asp that were identified by cloning analysis (Figure 4) . The clinicohematologic features, IPSS and outcome of the 27 patients with MDS/AML who carried FLT3/ITD, FLT3/TKD or Nras mutations are summarized in Table 2 . Taken together, the presence of FLT3 or N-ras mutations was detected in nine patients at initial presentation of MDS, which was restricted to RAEB, CMML or RAEB-T subtype. Another 21 patients acquired FLT3/ITD, FLT3/TKD or N-ras mutations at AML transformation. Coexistence of FLT3/TKD and N-ras mutations was found in two AML samples (nos. 13 and 14).
Correlation of clinical characteristics and outcome with status of FLT3 and N-ras mutations after AML transformation
A comparison of clinicohematologic features at AML stage between patients with and without FLT3 or N-ras mutations was made (Table 3) . No difference was observed with respect to age, Identification of two N-ras mutations, Gly12Ser and Gly12Asp in a patient. Cloning analysis was used to determine the first and second G to A substitution at codon 12 of N-ras gene (a). Two mutants, one containing Gly (GGT) to Ser (AGT) transition (b) and the other containing Gly (GGT) to Asp (GAT) transition (c) were identified. The sequences are read with the reverse primer. The survival after AML transformation in the entire group was 3.271.1 months for the 10 FLT3/ITD( þ ) patients and 6.670.9 months for the 60 FLT3/ITD(À) patients (P ¼ 0.084), 7.773.7 months for the four FLT3/TKD( þ ) patients and 6.270.9 months for the 61 FLT3/TKD(À) patients (P ¼ 0.741). Patients with N-ras mutations tended to have a longer survival than those without N-ras mutations (8.972.5 vs 5.470.8 months, P ¼ 0.0750). Of the 27 patients who received induction chemotherapy after AML transformation, there was no difference in the complete remission rate between patients with FLT3 or N-ras mutations and those without the mutations. The overall survival according to the mutation status of FLT3 and N-ras genes of the 27 patients receiving chemotherapy was 4.672.1 months for FLT3/ITD( þ ) compared to 11.371.7 months for FLT3/ITD(À) patients (P ¼ 0.030), 13.474.4 months for FLT3/TKD( þ ) compared with 9.871.6 months for FLT3/TKD(À) patients (P ¼ 0.752) and 9.571.4 months for N-ras mutation ( þ ) compared with 12.275.0 months for N-ras mutation (À) patients (P ¼ 0.285), respectively.
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Discussion
FLT3/ITD mutations are the most common genetic lesions found in AML patients with normal karyotypes and associated with an adverse outcome. [22] [23] [24] [25] [26] [27] The clinical and prognostic significance of the FLT3/ITD mutations in MDS is not clear. The incidence of FLT3/ITD in the cohort of our patients with MDS who later developed AML was low (6.1%) at initial presentation. Three groups have studied the FLT3/ITD mutations in adult MDS patients; 27, 28, 30 however, no data on AML transformation were available in these studies. On the other hand, the reported incidences of FLT3/ITD in patients with AML derived from MDS were 15.6% (12/77) and 11.8% (2/17), respectively, in two series; 30, 31 likewise, samples of MDS at presentation from the same individuals were not analyzed in the latter two studies. In the present study, we specially performed a comparative analysis of the matched paired marrow samples on FLT3/ITD mutations at both stages of the disease. We found that the frequency of FLT3/ITD mutations at AML transformation was 14.3%, significantly higher than that at presentation of MDS.
Of the three patients with FLT3/ITD at both MDS and AML phases, one had a much higher mutation level at AML stage as compared with that at MDS stage, suggesting that an overgrowth of the FLT3/ITD clone was responsible for the AML evolution. The other patient had identical three ITD mutations at both stages but the level of individual mutant changed, with one minor mutation at MDS becoming the major one at AML stage. This finding indicated that a subclone present at initial presentation might confer a growth advantage through clonal expansion when the disease progressed toward AML. One of the seven patients who acquired FLT3/ITD at AML transformation had a mutant level of more than 90%, suggesting acquisition of a biallelic mutation or deletion of wild type in the progression of AML. 26 The observations of acquisition of FLT3/ITD or changes of mutation patterns and the great variation in the mutant levels of FLT3/ITD during AML evolution were very similar to the findings that we have observed in de novo AML on relapse. 42 Comparison of FLT3/ITD mutation status and clinical characteristics in patients at diagnosis of MDS revealed that FLT3/ ITD was not associated with any of the clinicohematologic features. Although FLT3/ITD was restricted to RAEB, CMML or RAEB-T, there was no significant correlation between the FAB subtype and FLT3/ITD mutation because of the small number of patients carrying the ITD mutation. The clinicohematologic features according to the FLT3/ITD status were also analyzed in patients at AML stage. There were no significant differences in clinicohematologic features including age, sex, hemoglobin level or platelet count between ITD( þ ) and ITD(À) groups. Patients positive for FLT3/ITD had a significantly higher percentage of BM blasts, and marginally elevated WBC count and percentage of PB blasts as compared with patients negative for FLT3/ITD. As we always enriched for mononuclear cells from Table 3 Clinicohematologic characteristics and outcome according to FLT3 and N-ras mutation status in MDS with AML transformation 30 no comparative analysis on matched patient samples has yet been reported to support this notion. All five MDS patients who carried FLT3/ITD progressed to overt leukemia within 4 months with a mean of 2.5 months, more rapidly than those without FLT3/ITD. ITD( þ ) patients had a significantly poor survival than ITD(À) patients. Our results revealed that FLT3/ITD was associated with an adverse outcome in terms of rapid progression to AML and a shorter survival in patients with MDS. The prognostic relevance of FLT3/ITD mutation was also analyzed in patients after AML transformation. As a whole group, only marginal significance of survival difference was observed between FLT3/ITD( þ ) and FLT3/ITD(À) groups. When the analysis was limited to patients receiving induction chemotherapy, ITD( þ ) patients had a significantly shorter survival.
Mutations in the activation loop of the TKD of FLT3 have been described in exon 20 at codons 835/836 in MDS patients at initial presentation, 27, 28, 30 with Asp835Tyr being the most common mutation type. In the current series, only one patient with RAEB-T had an FLT3/TKD mutation of Asp835Tyr, accounting for a frequency of one in 27 (3.7%) RAEB-T patients who had AML progression later. Another three patients acquired Asp835His, Asp835Phe and Ile836Ser mutations, respectively, at AML transformation, the latter two types of FLT3/TKD have not been described before. As FLT3/TKD mutation occurred in only one patient prior to AML transformation, which precluded a meaningful statistical analysis of the clinical data. None of our patients had simultaneous ITD and TKD mutations. Taken together, 15.2% of patients who did not have FLT3 mutations at the time of diagnosis of MDS acquired the FLT3/ITD or FLT3/ TKD mutations during AML evolution, leading to a total of 20% (14/70) of our patients possessing FLT3/ITD or FLT3/TKD at the time of AML transformation.
With different mutation-detection techniques used and heterogeneous patient population studied, the reported incidences of N-ras mutations in MDS at presentation varied from 0 to 48%. [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] The higher incidences of the earlier studies were most detected by DNA amplification of exons 1 and 2 of N-ras gene followed by hybridization with oligonucleotide probes specific for each possible mutation. 8, [10] [11] [12] [17] [18] [19] The incidence of N-ras mutations detected by direct sequencing was much lower, ranging between 0 and 4.5% in the three series that included all subtypes of MDS but a relatively small number of patients; [13] [14] [15] another group described an incidence of 23.8% (5/21) on RAEB, CMML and RAEB-T subtypes. 9 As direct sequencing is the most unambiguous method of detecting ras mutations, we used direct sequencing for each PCR product containing codons 12 and 13 or 61 of N-ras gene. Our assay system allowed us to detect 2-5% N-ras mutant allele. We found that 6% (5/82) of MDS patients had N-ras mutations in the preleukemic clone, all but one retained the same N-ras mutant clone at AML stage and additional 16.9% (11/65) of patients gained N-ras mutations during the progression toward AML. On the other hand, we observed one patient losing N-ras mutations at AML transformation. There have been only two small longitudinal studies on Nras mutations in MDS, 10, 13 and both groups found that N-ras mutations might appear during the course of AML progression and one of them also observed loss of N-ras mutation after developing AML in one case. 10 Another group of investigators examined archived blood smears from MDS patients at various time points after initial presentation and found that three out of 90 patients acquired N-ras mutations during the course of MDS. 45 These observations suggest that N-ras mutations can be an early or late event in MDS, with more frequent occurrence as part of the clonal evolution during AML progression.
The N-ras mutations were also correlated with clinicohematologic features at diagnosis of MDS and AML, time to AML transformation and survival. The presence of N-ras mutations was not correlated with any feature at both stages except for the percentage of BM blasts, which was marginally lower at AML transformation in N-ras mutation ( þ ) patients than in N-ras mutation (À) patients. With respect to the prognostic relevance of N-ras mutations in MDS, some investigators observed that Nras mutations at presentation predicted an increased risk of AML transformation or poor survival, 8, 11, 16, 17, 19 whereas others did not find a correlation of N-ras mutation with poor prognosis or leukemia progression. 10, 18 In the cohort of our patients with MDS who later developed AML, we failed to find an association of N-ras mutation with a poor outcome either at the MDS or AML stage.
It is of interest to investigate the multiplicity of genetic alterations associated with leukemia progression. Simultaneous analysis of FLT3/ITD, FLT3/TKD and N-ras mutations in our patients revealed no concomitant mutations of these genes at diagnosis of MDS, suggesting that alterations of these genes played a role at the earliest phase of MDS in a non-cooperative manner in a subset of patients. At the time of AML transformation, we found that samples harboring FLT3/ITD did not have FLT3/TKD or N-ras mutations. It was worth noting that one patient (no. 8) acquired FLT3/ITD at AML transformation when she lost N-ras mutation. It was conceivable that the leukemia clone carrying N-ras mutation in this patient was outgrown by a clone harboring FLT3/ITD. We also observed that two samples harbored both FLT3/TKD and N-ras mutations at AML progression, suggesting that alterations of both genes could exert their effects on leukemia progression in a collaborative manner. Taken together, the present results showed that FLT3/ITD, FLT3/ TKD or N-ras mutations occurred independently or additively at AML transformation in 27 of 70 MDS patients. It has been demonstrated that both FLT3/ITD and FLT3/TKD mutations result in constitutive activation of the FLT3 kinase and the downstream targets including STATS, RAS/MAPK and PI3K/ AKT; [32] [33] [34] [35] [36] our data indicated that disturbance of Ras signaling pathways, either directly through N-ras mutations or indirectly through FLT3 mutations, plays a role in the pathogenesis of AML evolution in MDS. Recently, Gilliland and Griffin hypothesized a 'two-hit' model of leukemogenesis, one class of mutations, that is, FLT3 or ras mutations, confers a proliferation and survival benefit to leukemia clones; the other class of mutations appears to impair hematopoietic differentiation. 46 For those who did not have FLT3 or N-ras mutations at AML transformation, other genetic alterations may play a key role in the progression of AML.
In conclusion, we present here a study of multiple molecular markers in a cohort of MDS patients who later had AML transformation. Our results showed that FLT3/ITD, FLT3/TKD or N-ras mutations were rare in MDS at presentation but 33.9% of patients with MDS who did not have these mutations at the time of diagnosis of MDS acquired the mutations during progression to AML. The use of matched patient samples in the current study solidifies the evidence that acquisition of FLT3 or N-ras mutations is frequently associated with transformation from MDS to AML. We also demonstrate that FLT3/ITD mutation predicts an adverse outcome in MDS, whereas FLT3/TKD and N-ras mutations do not appear to have prognostic impact.
